Drug Profile
Research programme: NMDA receptor antagonists - AstraZeneca
Alternative Names: N-methyl-D-aspartate receptor antagonists - AstraZenecaLatest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator AstraZeneca
- Class
- Mechanism of Action NMDA receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Neuropathic pain; Pain
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Neuropathic-pain in USA (PO)
- 16 Jul 2016 No recent reports of development identified for preclinical development in Pain in USA (PO)